Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy
Metrics: PDF 448 views | HTML 1317 views | ?
Annelot G.J. van Rossum1, Marleen Kok2,3, Danielle McCool1, Mark Opdam1, Nienke C. Miltenburg4, Ingrid A.M. Mandjes5, Elise van Leeuwen-Stok6, Alex L.T. Imholz7, Johanneke E.A. Portielje8, Monique M.E.M. Bos9, Aart van Bochove10, Erik van Werkhoven11, Marjanka K. Schmidt1, Hendrika M. Oosterkamp12,* and Sabine C. Linn1,3,13,*
1Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands
2Division of Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands
3Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
4Department of Neurology, Medical Center Slotervaart, Amsterdam, The Netherlands
5Data Center, Netherlands Cancer Institute, Amsterdam, The Netherlands
6Dutch Breast Cancer Research Group, BOOG Study Center, Amsterdam, The Netherlands
7Department of Medical Oncology, Deventer Ziekenhuis, Deventer, The Netherlands
8Department of Medical Oncology, HagaZiekenhuis, The Hague, The Netherlands
9Department of Medical Oncology, Reinier de Graaf Groep, Delft, The Netherlands
10Department of Medical Oncology, Zaans Medisch Centrum, Zaandam, The Netherlands
11Biometrics Division, Netherlands Cancer Institute, Amsterdam, The Netherlands
12Department of Medical Oncology, Haaglanden Medisch Centrum, The Hague, The Netherlands
13Department of Pathology, University Medical Center, Utrecht, The Netherlands
*These authors contributed equally to this work
Sabine C. Linn, email: email@example.com
Keywords: replication; single nucleotide polymorphisms; association; toxicity; chemotherapy
Received: April 13, 2017 Accepted: October 27, 2017 Published: November 27, 2017
Introduction: Although pharmacogenomics has evolved substantially, a predictive test for chemotherapy toxicity is still lacking. We compared the toxicity of adjuvant dose-dense doxorubicin-cyclophosphamide (ddAC) and docetaxel-doxorubicin-cyclophosphamide (TAC) in a randomized multicenter phase III trial and replicated previously reported associations between genotypes and toxicity.
Results: 646 patients (97%) were evaluable for toxicity (grade 2 and higher). Whereas AN was more frequent after ddAC (P < 0.001), TAC treated patients more often had PNP (P < 0.001). We could replicate 2 previously reported associations: TECTA (rs1829; OR 4.18, 95% CI 1.84-9.51, P = 0.001) with PNP, and GSTP1 (rs1138272; OR 2.04, 95% CI 1.13-3.68, P = 0.018) with PNP.
Materials and methods: Patients with pT1-3, pN0-3 breast cancer were randomized between six cycles A60C600 every 2 weeks or T75A50C500 every 3 weeks. Associations of 13 previously reported single nucleotide polymorphisms (SNPs) with the most frequent toxicities: anemia (AN), febrile neutropenia (FN) and peripheral neuropathy (PNP) were analyzed using logistic regression models.
Conclusions: In this independent replication, we could replicate an association between 2 out of 13 SNPs and chemotherapy toxicities. These results warrant further validation in order to enable tailored treatment for breast cancer patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.